

Nixon & Vanderhye PC


ATTORNEYS AT LAW

8TH FLOOR
1100 NORTH GLEBE ROAD
ARLINGTON, VIRGINIA 22201-4714TELEPHONE: (703) 816-4000
FACSIMILE: (703) 816-4100
WRITER'S DIRECT DIAL NUMBER:
(703) 816-4091**FACSIMILE COVER SHEET**
PLEASE DELIVER IMMEDIATELY!!!!

Our Ref.: 2551-130
 Your Ref.: Appln No. 10/685,435 Date: April 13, 2004
 To: Office of Initial Patent Examination's Filing Receipt
Corrections
 Firm: USPTO
 Facsimile No.: Facsimile No.: (703) 746-9195
 From: B. J. Sadoff

Number of Pages (including cover sheet): 4(IF YOU DO NOT RECEIVE ALL OF THE PAGES OR ENCOUNTER DIFFICULTIES IN TRANSMISSION,
PLEASE CONTACT US IMMEDIATELY AT (703-816-4000).**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper and any noted attachments are being facsimile transmitted to the Patent and Trademark Office on April 9, 2004.



B. J. Sadoff

ATTACHMENT/S: Request for Correction of Updated Filing Receipt and Marked-up Copy of Updated Filing Receipt dated 3/24/04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE			
In re Patent Application of			
MAERTENS et al.		Atty. Ref.:	2551-130
Serial No.	10/685,435	Group:	1648
Filed:	October 16, 2003	Examiner:	
For:	MULTI-MER PEPTIDES DERIVED FROM HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC USE AND VACCINATION PURPOSES		

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by telephone to arrange for return of the original documents to us.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al.

Atty. Ref.: 2551-130

Serial No. 10/685,435

TC/A.U.: 1648

Filed: October 16, 2003

Examiner: Unassigned

For: MULTI-MER PEPTIDES DERIVED FROM HEPATITIS C VIRUS
ENVELOPE PROTEINS FOR DIAGNOSTIC USE AND
VACCINATION PURPOSES

April 13, 2004

Office of Initial Patent Examination's
Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA FACSIMILE
(703) 746-9195

Sir:

REQUEST FOR CORRECTION OF UPDATED FILING RECEIPT


Enclosed is a copy of the Updated Filing Receipt for the above-identified application which incorrectly states the city of residence of the second inventor as "Dealalbergen". It should read "Destelbergen" as stated in the Declaration filed with the application on October 16, 2003. A marked-up copy of the Updated Filing Receipt mailed March 24, 2004, is attached wherein the changes are shown in hand-written text. Please note your records accordingly.

Correction of same is respectfully requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



B. J. Sadoff
Reg. No. 36,663

BJS:pp

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

BJS

2551-130



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/685,435	10/16/2003	1648	1322	2551-130	4	9	5

23117
 NIXON & VANDERHYE, PC
 1100 N GLEBE ROAD
 8TH FLOOR
 ARLINGTON, VA 22201-4714

CONFIRMATION NO. 5780

UPDATED FILING RECEIPT



OC000000012169775

Date Mailed: 03/24/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Geert Maertens, Brugge, BELGIUM;
 Erik Depia, Destelbergen, BELGIUM;

Destelbergen

Assignment For Published Patent Application

N.V. INNOGENETICS S.A., Ghent, BELGIUM;

Domestic Priority data as claimed by applicant

This application is a DIV of 09/566,268 05/05/2000
 which is a CON of PCT/EP98/07105 11/06/1998

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 97870179.5 11/06/1997

If Required, Foreign Filing License Granted: 12/16/2003

Projected Publication Date: 07/01/2004

Non-Publication Request: No

Early Publication Request: No

Title

Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).